Similarly, TAMs in ovarian tumors and ascites produce abundant CCL22, attracting Tregs and suppressing immune surveillance, whereas CCL22 inhibitors reduce T cell migration (57). This evidence concerns the gene CCL22 and ovarian neoplasm.